Drug Information

Drug General Information
Drug ID
D02IWC
Former ID
DCL000464
Drug Name
AZD2624
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Discontinued in Phase 2 [522334], [541098]
Company
AstraZeneca
Structure
Download
2D MOL
Formula
C26H25N3O3S
InChI
InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1
InChIKey
QYTBBBAHNIWFOD-NRFANRHFSA-N
PubChem Compound ID
23649245
PubChem Substance ID
46520831, 56028527, 137895626, 172113554, 178102400, 198974890, 224156816, 229591064, 243562193, 251962985
Target and Pathway
Target(s) Nigral tachykinin NK(3) receptor Target Info Modulator
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Reactome G alpha (q) signalling events
WikiPathways Gastrin-CREB signalling pathway via PKC and MAPK
Peptide GPCRs
GPCR ligand binding
GPCR downstream signaling
References
Ref 522334ClinicalTrials.gov (NCT00686998) Phase IIA Study in Patients With Schizophrenia. U.S. National Institutes of Health.
Ref 541098(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5775).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.